K. Isakova

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.

H. Linden, G. Hortobagyi, L. Pusztai, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)

H. Linden, G. Hortobagyi, D. Tripathy, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313).

H. Linden, G. Hortobagyi, W. Barlow, 2017 .

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

A. Godwin, B. Kimler, Q. Khan, 2023, npj Breast Cancer.

Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).

A. Godwin, B. Kimler, D. Koestler, 2023, Journal of Clinical Oncology.